Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference
RPID 01.07.2025
Date of Upcoming Event:2025-01-16
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
About Gravity Analytica
LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rdAnnual J.P. Morgan Healthcare Conference.
The Company is scheduled to present on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website athttps://investors.rapidmicrobio.com/and can be accessedhere. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visitwww.rapidmicrobio.comor follow the Company on X (formerly known as Twitter) at@rapidmicrobioor onLinkedIn.
Investor Contact:Michael Beaulieu, CFAVice President, Investor Relations and Corporate Communicationsmbeaulieu@rapidmicrobio.comMedia Contact:media@rapidmicrobio.com